Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus

Progress in Neurobiology

Volumn 101-102, Issue 1, 2013, Pages 46-64

  Mecha, Miriam ^a   Carrillo Salinas, Francisco J ^a   Mestre, Leyre ^a   Feliú, Ana ^a   Guaza, Carmen ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

Axonal damage; Brain pathology; Demyelination; Multiple sclerosis; Neuroinflammation; Spinal cord pathology; Theiler's virus

Indexed keywords

KALLIKREIN 6; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; AXONAL INJURY; CANINE DISTEMPER MORBILLIVIRUS; CD8+ T LYMPHOCYTE; CHICKENPOX; CORONAVIRUS; DEMYELINATION; DISEASE ASSOCIATION; DISEASE COURSE; EPSTEIN BARR VIRUS; HERPES COMPLEX VIRUS; HERPES ZOSTER; HUMAN HERPESVIRUS 6; HUMAN T CELL LEUKEMIA VIRUS 1; INFLAMMATION; INFLAMMATORY INFILTRATE; MACROPHAGE; MARDIVIRUS; MEASLES VIRUS; MICROGLIA; MOLECULAR MIMICRY; MONOCYTE; MULTIPLE SCLEROSIS; MUMPS VIRUS; MURINE ENCEPHALOMYELITIS VIRUS; MURINE HEPATITIS CORONAVIRUS; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL; REMYELINIZATION; REVIEW; SEMLIKI FOREST ALPHAVIRUS; SIMIAN PARAINFLUENZA VIRUS 5; SINDBIS VIRUS; VARICELLA ZOSTER VIRUS; WHITE MATTER LESION;

ANIMALS; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MICE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; THEILOVIRUS;

EID: 84873200178     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.11.003     Document Type: Review

References (244)

1. Adami C., Pooley J., Glomb J., Stecker E., Fazal F., Fleming J.O., Baker S.C. Evolution of mouse hepatitis virus (MHV) during chronic infection: quasispecies nature of the persistent MHV RNA. Virology 1995, 209:337-346.
2. Ahlgren C., Odén A., Berströmg T., Lycke J. Serum and CSF measles antibody levels increase over time in multiple sclerosis or clinically isolated syndrome. Journal of Neuroimmunology 2012, 247:70-74.
3. Allen I., Brankin B. Pathogenesis of multiple sclerosis: the immune diathesis and the role of viruses. Journal of Neuropathology and Experimental Neurology 1993, 52:95-105.
4. Amor S., Scallan M.F., Morris M.M., Dyson H., Fazakerley J.K. Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis. Journal of General Virology 1996, 77:281-291.
5. Arévalo-Martín A., Vela J.M., Molina-Holgado E., Borrell J., Guaza C. Therapeutic actions of cannabinoids in a murine model of multiple sclerosis. Journal of Neuroscience 2003, 23:2511-2516.
6. Asakura A., Miller D.J., Pease L.R., Rodriguez M. Targeting of IgM kappa antibodies to oligodendrocytes promotes CNS remyelination. Journal of Neuroscience 1998, 18:7700-7708.
7. Asakura A., Miller D.J., Poqulis R.J., Pease L.R., Rodriguez M. Oligodendrocyte reactive O1, O4, and HNK 1 monoclonal antibodies are encoded by germline immunoglobulins genes. Brain Research. Molecular Brain Research 1995, 34:283-293.
8. Ascherio A., Munger K.L., Lennette E.T., Spiegelman D., Hernan M.A., Olek M.J., Hankinson S.E., Hunter D.J. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. Journal of the American Medical Association 2001, 291:1875-1879.
9. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Annals of Neurology 2007, 61:288-299.
10. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Annals of Neurology 2007, 61:504-513.
11. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohfeld R., Friese M., Schroder R., Deckert M., Schmidt S., Ravid R., Rajewsky K. Clonal expansions of CD8+ T cells dominate the cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. Journal of Experimental Medicine 2000, 192:393-404.
12. Baker D., Amor S. Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2011, 242:78-83.
13. Barnett M.H., Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Annals of Neurology 2004, 55:458-468.
14. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nature Reviews Immunology 2007, 7:904-912.
15. Begolka W.S., Vanderlug C.L., Rahbe S.M., Miller S.D. Differential expression of inflammatory cytokines parallels progression of central nervous system in two clinically distinct models of multiple sclerosis. Journal of Immunology 1998, 161:4437-4446.
16. Bender S.J., Weiss S.R. Pathogenesis of murine coronavirus in the central nervous system. Journal of NeuroImmune Pharmacology 2010, 5:336-354.
17. Bergmann C.C., Lane T.E., Stohlman S.A. Coronavirus infection of the central nervous system: host-virus stand-off. Nature Reviews Microbiology 2006, 4:121-132.
18. Bieber A.J., Warrington A., Asakura K., Criric B., Kaveri S.V., Pease L.R., Rodriguez M. Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia 2002, 37:241-249.
19. Bieber A.J., Ure D.R., Rodriguez M. Genetically dominant spinal cord repair in a murine model of chronic progressive multiple sclerosis. Journal of Neuropathology and Experimental Neurology 2005, 64:46-57.
20. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000, 123:1174-1183.
21. Blakemore W.F. Regeneration and repair in multiple sclerosis: the view of experimental pathology. Journal of the Neurological Sciences 2008, 265:1-4.
22. Boucher A., Desforges M., Duquette P., Talbot P.J. Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients. Clinical Immunology 2007, 23:258-267.
23. Bougiouklis P.A. Suggesting the possible role of Turkey herpes virus or HVT like as a predisposing factor or causative agent in multiple sclerosis. Medical Hypotheses 2006, 67:926-929.
24. Brahic M., Bureau J.F., Michiels T. The genetics of the persistent infection and demyelinating disease caused by Theiler's virus. Annual Review of Microbiology 2005, 59:279-298.
25. Brettschneider J., Tumani H., Kiechle U., Muche R., Richards G., Lehmensiek V., Ludolph A.C., Otto M. IgG antibodies against measles, rubella and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS ONE 2009, 4:e7638.
26. Brownell B., Hughes J.T. Distribution of plaques in the cerebrum in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1962, 25:315-320.
27. Brück W., Schmied M., Suchanek G., Brück Y., Breitschopf H., Poser S., Piddlesden S., Lassmann H. Oligodendrocytes in the early course of multiple sclerosis. Annals of Neurology 1994, 35:65-73.
28. Carlson N.G., Hill K.E., Tsunoda I., Fujinami R.S., Rose J.W. The pathological role for COX-2 in apoptotic oligodendrocytes in virus-induced demyelinating disease: implications for multiple sclerosis. Journal of Neuroimmunology 2006, 174:21-31.
29. Carlson N.G., Rojas M.A., Redd J.W., Tang P., Wood B., Hill K.E., Rose J.W. Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death. Journal of Neuroinflammation 2010, 7:25-36.
30. Carpentier P.A., Getts M., Miller S.D. Pro-inflammatory functions of astrocytes correlate with viral clearance and strain-dependent protection from TMEV-induced demyelinating disease. Virology 2008, 375:24-36.
31. Cash E., Chamorro M., Brahic M. Minus-strand RNA synthesis in the spinal cord of mice infected with Theiler's virus. Journal of Virology 1988, 62:1824-1826.
32. Centonze D., Muzio L., Rossi S., Cavasinni F., De Chiara V., Bergami A., Musella A., D'Amelio M., Cavallucci V., Martorana A., Bergamaschi A., Cencioni M.T., Diamantini A., Butti E., Comi G., Bernardi G., Cecconi F., Battistini L., Furlan R., Martino G. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. Journal of Neuroscience 2009, 29:3442-3452.
33. Cermelli C., Berti R., Soldan S.S., Mayne M., D'ambrosia J.M., Ludwin S.K., Jacobson S. High frequency of human herpes virus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. Journal of Infectious Diseases 2003, 187:1377-1387.
34. Challoner P.B., Smith K.T., Parker J.D., MacLeod D.L., Coulter S.N., Rose T.M., Schultz E.R., Bennett J.L., Garber R.L., Chang M., et al. Plaque-associated expression of human herpes virus 6 in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:7440-7444.
35. Charcot M. Histologie de la sclerose en plaques. Gazette Hôpitaux 1868, 141:554-557.
36. Chastain E., Duncan D., Rodgers J.M., Miller S.D. The role of antigen presenting cells in multiple sclerosis. Biochimica and Biophysica Acta 2011, 1812:265-274.
37. Chastain E., Miller S.D. Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease. Immunological Reviews 2012, 245:227-238.
38. Clach R.J., Miller S.D., Metzner R., Dal Canto M.C., Lipton H.L. Monocytes/macrophages isolated from the mouse central nervous system contain infectious Theiler's murine encephalomyelitis virus (TMEV). Virology 1990, 176:244-254.
39. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
40. Croxford J.L., Miller S.D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+Win55,212. Journal of Clinical Investigation 2003, 111:1231-1240.
41. Croxford J.L., Olson J.K., Miller S.D. Epitope spreading and molecular mimicry as triggers of autoimmunity in the Theiler's virus-induced demyelinating disease model of multiple sclerosis. Autoimmunity Review 2002, 1:251-260.
42. Dal Canto M.C., Barbano R.L. Remyelination during remission in Theiler's virus infection. American Journal of Pathology 1984, 116:30-45.
43. Dal Canto M.C., Kim S.D., Miller S.D., Melvod R.W. Theiler's murine encephalomyelitis virus (TMEV)-induced demyelination: a model for human multiple sclerosis. Methods 1996, 10:453-461.
44. Dal Canto M.C., Lipton H.L. Primary demyelination in Theiler's virus infection. An ultrastructural study. Laboratory Investigation 1975, 33:626-637.
45. Dal Canto M.C., Lipton H.L. Schwann cells remyelination and recurrent demyelination in the central nervous system of mice infected with attenuated Theiler's virus. American Journal of Pathology 1980, 98:101-122.
46. Dal Canto M.C., Lipton H.L. Ultrastructural immunohistochemical localization of virus in acute and chronic demyelinating Theiler's virus infection. American Journal of Pathology 1982, 106:20-29.
47. Daniels J.B., Pappenheimer A.M., Richardson S. Observations on encephalomyelitis of mice (DA strain). Journal of Experimental Medicine 1952, 96:517-530.
48. Deb C., Lafrance-Corey R.G., Zoecklein L., Papke L., Rodriguez M., Howe L.C. Demyelinated axons and motor function are protected by genetic deletion of perforin in a mouse model of multiple sclerosis. Journal of Neuropathology and Experimental Neurology 2009, 68:1037-1048.
49. + T cells cause disability and axonal loss in a mouse model of multiple sclerosis. PLoS ONE 2010, 5:e12478.
50. De Luca L.E., Pikor N.B., O'Leary J., Galicia-Rosas G., Ward L.A., Defreitas D., Finlay T.M., Ousman S.S., Osborne L.R., Gomerman J.L. Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis. Journal of Immunology 2010, 184:3174-3185.
51. Denic A., Johnson A.J., Bieber A.J., Warrington A.E., Rodriguez M., Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology 2010, 18:21-29.
52. Denic A., Pirko I., Wootla B., Bieber A., Macura S., Rodriguez M. Deletion of beta-2-microglobulin ameliorates spinal cord lesion load promotes recovery of brainstem NAA levels in a murine model of multiple sclerosis. Brain Pathology 2012, 22:698-708.
53. Denic A., Zoecklein L., Kerkvliet J., Papke L., Edukulla R., Warrington A., Bieber A., Pease L.R., David C.S., Rodriguez M. Transgenic expression of viral capsid proteins predisposes to axonal injury in a murine model of multiple sclerosis. Brain Pathology 2011, 21:505-515.
54. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007, 68:S13-S21.
55. 2 receptor activation. Molecular and Cellular Neuroscience 2007, 34:551-561.
56. Drescher K.M., Pease L.R., Rodriguez M. Antiviral immune responses modulate the nature of central nervous system (CNS) disease in a murine model of multiple sclerosis. Immunological Reviews 1997, 159:177-193.
57. Drescher K.M., Rivera-Quinones C., Lucchinetti C.F., Rodriguez M. Failure of treatment with linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis. Journal of Neuroimmunology 1998, 88:111-119.
58. Fazakerley J.K., Pathak S., Scallan M., Amor S., Dyson H. Replication of the A7 (74) strain of Semliki forest virus is restricted in neurons. Virology 1993, 195:627-637.
59. Fazakerley J.K., Webb H.E. Semliki Forest virus induced immune mediated demyelination: adoptive transfer studies and viral persistence in nude mice. Journal of General Virology 1987, 68:377-385.
60. Fazekas F., Deisenhammer F., Strasser-Fuchs S., Nahler G., Mamoli B. Randomised placebo controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997, 349:589-593.
61. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis. Nature Medicine 1997, 5:170-175.
62. Fernandez O., García-Merino J.A., Alvarez-Cermeño J.C., Arbizu T., Izquierdo G., Olascoaga J., Rodriguez-Antigüedad A., Prieto J.M., Oreja-Guevara C., Hernandez M.A., Montalbán X. Spanish consensus on the use on natalizumab (Tysabri). Neurología 2012, 27:432-441.
63. + cells to demyelination induced by coronavirus JHM. Regional Immunology 1993, 5:37-43.
64. Franklin R.J. Why does remyelination fail in multiple sclerosis?. Nature Reviews Neuroscience 2002, 9:705-714.
65. Friedmann A., Frankel G., Lorch Y., Steinman L. Monoclonal anti I-A antibody reverses chronic paralysis and demyelination in Theiler's virus infected mice: critical importance of timing of treatment. Journal of Virology 1987, 61:898-903.
66. Friese M.A., Montalban X., Willcox N., Bell J.I., Martin R., Fugger L. The value of animal models for drug development in multiple sclerosis. Brain 2006, 129:1940-1952.
67. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
68. Fujinami R.S., Oldstone M.B.A., Wroblewska Z., Frankel M.E., Koprowski H. Molecular mimicry in virus infection: crossreaction of Measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proceedings of the National Academy of Sciences of the United States of America 1983, 80:2346-2350.
69. Fujinami R.S., Rosenthal A., Lampert P.W., Zurbriggen A., Yamada M. Survival of athymic mice (nu/nu) after Theiler's murine encephalomyelitis virus infection by passive administration of neutralizing monoclonal antibody. Journal of Virology 1989, 63:2081-2087.
70. Fujinami R.S., Zurbriggen A., Powell H.C. Monoclonal antibody defines determinant between Theiler's virus and lipid-like structures. Journal of Neuroimmunology 1988, 20:25-32.
71. Getts M.T., Richards M.H., Miller S.D. A critical role for virus specific CD8+ CTLs in protection from Theiler's virus-induced demyelination in disease-susceptible SJL mice. Virology 2010, 402:102-111.
72. Geurts J.J., Bo L., Roosendaal S.D., Hazes T., Daniels R., Barkhof Witter M.P., Huitinga I., van der Valk P. Extensive hippocampal demyelination in multiple sclerosis. Journal of Neuropathology and Experimental Neurology 2007, 66:819-827.
73. Ghadge G.D., Wollmann R., Baida G., Traka M., Roos R.P. The L-coding region of DA strain of Theiler's murine encephalomyelitis virus causes disfunction and death of myelin synthesizing cells. Journal of Virology 2011, 85:9377-9384.
74. Goings G.E., Greismans A., James R.E., Abram L.K.F., Begolka W.S., Miller S.D., Szeele F.G. Hematopoietic cell activation in the subventricular zone after Theiler's virus infection. Journal of Neuroinflammation 2008, 5:44.
75. Goswami K.K., Lange L.S., Mitchell D.N., Cameron K.R., Rusell W.C. Does simian virus 5 infect humans?. Journal of General Virology 1984, 65:1295-1303.
76. Goverman J., Perchellet A., Huseby E.S. The role of CD8+ T cells in multiple sclerosis and its animal model. Current Drug Targets: Inflammation & Allergy 2005, 4:239-245.
77. Haile R., Smith P., Read D., Nassim D., Warlow C., Russell W.C. A study of measles virus and canine distemper virus antibodies, and of childhood infections in multiple sclerosis patients and controls. Journal of the Neurological Sciences 1982, 56:1-10.
78. Hirano A. Review of the morphological aspects of remyelination. Developmental Neuroscience 1989, 11:112-117.
79. Hosking M.P., Lane T.E. The pathogenesis of murine corona virus infection of the central nervous system. Critical Reviews in Immunology 2010, 30:119-130.
80. Howe C.L., Adelson J.D., Rodriguez M. Absence of perforin expression confers axonal protection despite demyelination. Neurobiology of Disease 2006, 25:354-359.
81. Howe C.L., Ure D., Adelson J.D., Lafrance-Corey R., Johnson A., Rodriguez M. CD8 T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in viral model of fulminant demyelination. Journal of Neuroimmunology 2007, 188:13-21.
82. Huseby E.S., Liggit D., Bratt T., Schnabel B., Ohlén C., Goverman J. A pathogenic role for myelin-specific CD8 T cells in a model for multiple sclerosis. Journal of Experimental Medicine 2001, 194:669-676.
83. Inoue A., Koh C.S., Yamazaki M., Ichikawa M., Isobe M., Ishihara Y., Yagita H., Kim B.S. Anti-adhesion molecule therapy in Theiler's murine encephalomyelitis virus-induced demyelinating disease. International Immunology 1997, 9:1837-1847.
84. Jack C., Antel J., Brück W., Kuhlmann T. Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis. Glia 2007, 9:926-934.
85. Jelachich M.L., Bandyopadhyay P., Blum K., Lipton H.L. Theiler's virus growth in murine macrophage cell lines depends on the state of differentiation. Virology 1995, 209:437-444.
86. Jelachich M.L., Bramlage C., Lipton H.M. Differentiation of M1 myeloid precursor cells into macrophages results in binding and infection by Theiler's murine encephalomyelitis virus and apoptosis. Journal of Virology 1999, 73:3227-3235.
87. + T-cell response in patients with early multiple sclerosis. Brain 2008, 13:1712-1721.
88. + T cell response to RNA polymerase in susceptible SJL/J mice. Journal of Virology 2009, 83:1398-1409.
89. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B. Copolymer-1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double blind, placebo-controlled trial. The Copolymer-1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
90. Jordan C.A., Friedrich V.L., Godfraind C., Cardellechio C.B., Holmes K.V., Dubois-Dalq M. Expression of viral and myelin transcripts in a murine CNS demyelinating disease caused by a coronavirus. Glia 1989, 2:318-329.
91. Kang B.S., Lyman M.A., Kim B.S. Differences in avidity and epitope recognition of CD8 (+) T cells infiltrating the central nervous systems of SJL/J mice infected with BeAn and DA strains of Theiler's murine encephalomyelitis virus. Journal of Virology 2002, 76:11780-11784.
92. Kappel C.A., Melvod R.W., Kim B.S. Influence of sex on susceptibility in the Theiler's encephalomyelitis virus model for multiple sclerosis. Journal of Neuroimmunology 1990, 29:15-19.
93. Karpus W.J., Pope J.G., Peterson J.D., Dal Canto M.C., Miller S.D. Inhibition of Theiler's virus-mediated demyelination by peripheral immune tolerance induction. Journal of Immunology 1995, 155:947-957.
94. Katz-Levy Y., Neville K.L., Girvin A.M., Vanderlugt C.L., Pope J.G., Tan L.J., Miller S.D. Endogenous presentation of self-myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. Journal of Clinical Investigation 1999, 104:599-610.
95. Kieseier B.C., Hartung H.P. Current disease-modifying therapies in multiple sclerosis. Seminars in Neurology 2003, 23:133-146.
96. Knobler R.L., Dubois-Dalq M., Haspel M.V., Lampert P.W., Claysmith A.P., Oldstone M.B. Selective localization of wild type and mutant mouse hepatitis virus (JHV strain) antigens in CNS tissue by fluorescence, light and electron microscopy. Journal of Neuroimmunology 1981, 1:81-92.
97. Knox K.K., Brewer J.H., Henry J.M., Harrington D.L., Carrigan D.R. Human herpes virus 6 and multiple sclerosis: systemic active infections in patients with early disease. Clinical Infectious Diseases 2000, 31:894-903.
98. Kurtzke J.F. Epidemiologic evidence for multiple sclerosis as an infection. Clinical Microbiology Reviews 1993, 6:382-427.
99. Kutzelnigg A., Lassman H. Cortical lesions and brain atrophy in MS. Journal of the Neurological Sciences 2005, 233:55-59.
100. Kutzelnigg A., Lassman H. Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits?. Journal of the Neurological Sciences 2006, 245:123-126.
101. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. Journal of Experimental Medicine 2005, 201:233-240.
102. Lassmann H. What drives disease in multiple sclerosis: inflammation or neurodegeneration?. Clinical and Experimental Neuroimmunology 2010, 1:2-11.
103. Lavi E., Gilden D.H., Wroblewska Z., Rorke L.B., Weiss S.R. Experimental demyelination produced by the A59 strain of mouse hepatitis virus. Neurology 1984, 34:597-603.
104. Li J., Baud O., Vartanian T., Volpe J.J., Rosenberg P.A. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:9936-9941.
105. Lin X., Njenga M.K., Johnson A.J., Pavelko K.D., David C.S., Pease L.R., Rodriguez M. Transgenic expression of Theiler's virus encephalomyelitis virus genes in H-2 (b) mice inhibits resistance to virus-induced demyelination. Journal of Virology 2002, 76:7799-7811.
106. Lindsley M.D., Rodriguez M. Characterization of the inflammatory response in the central nervous system of mice susceptible or resistant to demyelination by Theiler's virus. Journal of Immunology 1989, 142:2677-2682.
107. Lipton H.L. Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infection and Immunity 1975, 11:1147-1155.
108. Lipton H.L., Dal Canto M.C. Theiler's virus-induced demyelination: prevention by immunosuppression. Science 1976, 192:62-64.
109. Lipton H.L., Twaddle G., Jelachich M.L. The predominant virus antigen burden is present in macrophages in Theiler's murine encephalomyelitis virus-induced demyelinating disease. Journal of Virology 1995, 69:2525-2533.
110. Liu Y., Zhang X. Murine coronavirus-induced oligodendrocyte apoptosis is mediated though the activation of the Fas signaling pathway. Virology 2007, 360:364-375.
111. Liuzzi G.M., Riccio P., Dal Canto M.C. Release of myelin basic protein-degrading proteolytic activity from microglia and macrophages after infection with Theiler's murine encephalomyelitis virus: comparison between susceptible and resistant mice. Journal of Neuroimmunology 1995, 62:91-102.
112. Loría F., Petrosino S., Hernangómez M., Mestre L., Spagnolo A., Correa F., Di Marzo V., Docagne F., Guaza C. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiology of Disease 2010, 37:166-176.
113. Lucas R.M., Hughes A.M., Lay M.L., Ponsonby A.L., Dwyer D.E., Taylor B.V., Pender M.P. Epstein-Barr virus and multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 2011, 82:1142-1148.
114. Lucchinetti C.F., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of Neurology 2000, 47:707-717.
115. Lucchinetti C.F., Popescu B.F., Bunyan R.F., Moll N.M., Roemer S.F., Lassmann H., Brück W., Parisi J.E., Scheithauer B.W., Giannini C., Weigand S.D., Mandrekar J., Ransohoff R.M. Inflammatory cortical demyelination in early multiple sclerosis. New England Journal of Medicine 2011, 365:2188-2197.
116. Lumsden C.E. The neuropathology of multiple sclerosis. Handbook of Clinical Neurology 1970, 217-309. Elsevier, New York. P.J. Vinken, G.W. Bruyn (Eds.).
117. Lünemman J.D., Tintoré M., Messmer B., Strowig T., Rovira A., Perkal H., Caballero E., Münz C., Montalban X., Comabella M. Elevated Epstein-Barr virus encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Annals of Neurology 2010, 67:159-169.
118. + T cell responses to Theiler's murine encephalomyelitis virus between resistant C57BL/6 and susceptible SJL/J mice. European Journal of Immunology 2004, 34:2730-2739.
119. Mack C.L., Vanderlugt-Castaneda C.L., Neville K., Miller S.D. Microglia are activated to become competent antigen presenting and effector cells in the inflammatory environment of the Theiler's virus model of multiple sclerosis. Journal of Neuroimmunology 2003, 144:68-79.
120. MacKenzie-Graham A., Tiwari-Woodruff S.K., Sharma G., Aguilar C., Vo K.T., Strickland L.V., Morales L., Fubara B., Martin M., Jacobs R.E., Johnson G.A., Toga A.W., Voskuhl R.R. Purkinje cell loss in experimental autoimmune encephalomyelitis. Neuroimage 2009, 48:637-651.
121. Mandolesi G., Grasselli G., Musella A., Gentile S.A., Musumeci G., Sepman H., Haji N., Fresegna D., Bernardi G., Centonze D. Gabaergic signaling and connectivity on Purkinje cells are impaired in experimental autoimmune encephalomyelitis. Neurobiology of Disease 2012, 46:414-424.
122. McDonald W.I. Remyelination in relation to clinical lesions of the central nervous system. British Medical Bulletin 1974, 30:186-189.
123. McGavern D.B., Murray P.D., Rivera-Quiñones C., Schmelzer J.D., Low P.A., Rodríguez M. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 2000, 123:519-531.
124. McGavern D.B., Murray P.D., Rodriguez M. Quantification of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury. Journal of Neuroscience Research 1999, 58:492-504.
125. McMahon E.J., Bailey S.L., Castaneda C.V., Waldner H., Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nature Medicine 2005, 11:335-339.
126. Marten N.W., Stohlman S.A., Bergmann C.C. MHV infection of the CNS: mechanisms of immune mediated control. Viral Immunology 2001, 14:1-18.
127. Martinez A., Alvarez-Lafuente R., Mas A., Bartolomé M., García Montojo M., De las Heras V., de la Concha E.G., Arroyo R., Urcelay E. Environment-gene interaction in multiple sclerosis: human herpes virus 6 and MHC2TA. Human Immunology 2007, 68:685-689.
128. Matute C., Alberdi E., Domercq M. The link between excitotoxic oligodendroglial death and demyelinating disease. Trends in Neurosciences 2001, 24:224-230.
129. Melin A., Outteryck O., Collongues N., Zéphir H., Fleury M.C., Blanc F., Lacour A., Ongagna J.C., Berteloot A.S., Vermersch P., de Sèze J. Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing remitting multiple sclerosis. Journal of Neurology 2012, 259:1215-1221.
130. +T cells response against a single immunodominant viral peptide. European Journal of Immunology 2003, 33:2501-2510.
131. Metcalf T.U., Griffin D.E. Alphavirus induced-encephalomyelitis: antibodies secreting cells and viral clearance from the nervous system. Journal of Virology 2011, 85:11450-11490.
132. Miller D.J., Rodriguez M. Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Microscopy Research and Technique 1995, 32:230-245.
133. Miller D.J., Sanborn K.S., Katmann J.A., Rodriguez M. Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis. Journal of Neuroscience 1994, 14:6230-6238.
134. Miller S.D., Vanderlugt C.L., Begolka W.S., Pao W., Yauch R.L., Neville K.L., Katz-Levy Y., Carrizosa A., Kim B.S. Persistent infection of Theiler's virus leads to CNS autoimmunity via epitope spreading. Nature Medicine 1997, 3:1133-1136.
135. Mokhtarian F., Grob D., Griffin D.E. Role of the immune response in Sindbis virus-induced paralysis of SJL/J mice. Journal of Immunology 1989, 143:633-637.
136. Mokhtarian F., Huan C.M., Roman C., Raine C.S. Semliki forest virus-induced demyelination and remyelination involvement of B cells and antimyelin antibodies. Journal of Neuroimmunology 2003, 137:19-31.
137. Moreno B., Espejo C., Mestre L., Suardiaz M., Clemente D., de Castro F., Fernández-Fernández O., Montalbán X., Villoslada P., Guaza C. Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis. Spanish Net Work for MS. Revista de Neurologia 2012, 54:114-121.
138. Munger K.L., Levin L.I., O'Reilly E.J., Falk K.I., Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Multiple Sclerosis 2011, 10:1185-1193.
139. Murray P.D., Pavelko K.D., Lin X., Leibowitz J., Rodriguez M. CD4+ and CD8+ make discrete contributions to demyelination and neurological disease in a viral model of multiple sclerosis. Journal of Virology 1998, 72:7320-7329.
140. Nait-Oumesmar B., Picard-Riera N., Kerninon C., Decker L., Seilhean D., Höglinger G.U., Hirsch E.C., Reynolds R., Baron-Van Evercooren A. Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:4694-4699.
141. Neville K.L., Padilla J., Miller S.D. Myelin-specific tolerance attenuates the progression of a virus-induced demyelinating disease: implications for the treatment of MS. Journal of Neuroimmunology 2002, 123:18-29.
142. Njenga M.K., Asakura K., Hunter S.F., Wettstein P., Pease L.R., Rodriguez M. The immune system preferentially clears Theiler's virus from the gray matter of the central nervous system. Journal of Virology 1997, 71:8592-8601.
143. Njenga M.K., Coenen M.J., DeCuir N., Yeh H.Y., Rodriguez M. Short-term treatment with interferon alpha/beta promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis. Journal of Neuroscience Research 2000, 59:661-670.
144. Njenga M.K., Murray P.D., McGavern D., Lin X., Drescher K.M., Rodriguez M. Absence of spontaneous central nervous system remyelination in class II-deficient mice infected with Theiler's virus. Journal of Neuropathology and Experimental Neurology 1999, 58:78-91.
145. Njenga M.K., Pavelko K.D., Baisch J., Lin X., David C., Leibowitz J., Rodriguez M. Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice. Journal of Virology 1996, 70:1729-1737.
146. Noseworthy J.H., Lucchinetti C.F., Rodríguez M., Weinshenker B.G. Multiple sclerosis. New England Journal of Medicine 2000, 343:938-952.
147. Oger J. HTLV-1 infection and the viral etiology of multiple sclerosis. Journal of the Neurological Sciences 2007, 262:100-104.
148. Oleszak E.L., Chang J.R., Friedamn H., Katsetos C.D., Platsoucas C.D. Theiler's virus infection: a model for multiple sclerosis. Clinical Microbiology Reviews 2004, 17:174-207.
149. Olson J.K., Croxford J.L., Caleboff M., Dal Canto M.C., Miller S.D. A virus-induced molecular mimicry model of multiple sclerosis. Journal of Clinical Investigation 2001, 108:311-318.
150. Olson J.K., Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses trough multiple TLRs. Journal of Immunology 2004, 173:3916-3924.
151. Olson J.K., Miller S.D. The innate immune response affects the development of the autoimmune response in Theiler's virus-induced demyelinating disease. Journal of Immunology 2009, 182:5712-5722.
152. Ortega-Gutiérrez S., Molina-Holgado E., Arévalo-Martín A., Viso A., López-Rodriguez M.L., Guaza C. Endocannabinoids uptake inhibition as therapeutic approach in a murine model of multiple sclerosis. FASEB Journal 2005, 19:1338-1440.
153. O'Shea H., Crang J., Tonks P., Nash A., Fazakerley J.K. The PI capsid region of Theiler's virus controls replication in mouse glial cells cultures. Archives of Virology 1997, 142:1521-1535.
154. Ozawa K., Suchanek G., Breitschopf H., Brück W., Budka H., Jellinger K., Lassmann H. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994, 117:1311-1322.
155. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 18:893-895.
156. Pathak S., Webb H.E. Semliki Forest virus multiplication in oligodendrocytes in mouse brain with reference to demyelination. Journal of Physiology 1983, 339:17-27.
157. Paty D.W., Li D.K. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. II MRI analysis results of a multicenter, randomized, double blind, placebo controlled trial. UBC MS/MRI Study Group and the Interferon beta Multiple Sclerosis Study Group. Neurology 1993, 43:662-667.
158. Pavelko K.D., Pease L.R., David C.S., Rodriguez M. Genetic deletion of a single immunodominant T-cell response confers susceptibility to virus-induced demyelination. Brain Pathology 2007, 2:184-196.
159. Paya C.V., Leibson P.J., Patick A.K., Rodriguez M. Inhibition of Theiler's virus-induced demyelination in vivo by tumor necrosis alpha. International Immunology 1990, 2:909-913.
160. Pena-Rossi C., Delcroix M., Huitinga I., McAllister A., Van Rooijen N., Classen E., Brahic M. Role of macrophages during Theiler's virus infection. Journal of Virology 1997, 71:3336-3340.
161. Perron H., Germi R., Bernard C., Garcia-Montojo M., Deluen C., Farinelli L., Faucard R., Veas F., Stefas I., Fabriek B.O., Van-Horssen J., Van-der-Valk P., Gerdil C., Mancuso R., Saresella M., Clerici M., Marcel S., Creange A., Cavaretta R., Caputo D., Arru G., Morand P., Lang A.B., Sotgiu S., Ruprecht K., Rieckmann P., Villoslada P., Chofflon M., Boucraut J., Pelletier J., Hartung H.P. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Multiple Sclerosis 2012, PMID 22457345.
162. Perron H., Lang A. The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clinical Reviews in Allergy and Immunology 2010, 39:51-61.
163. Perron H., Suh M., Lalande B., Gratacap B., Laurent A., Stoebner P., Seigneurin J.M. Herpes simplex virus ICP0 and ICP4 immediate early proteins strongly enhance expression of a retrovirus harboured by a leptomeningeal cell line from a patient with multiple sclerosis. Journal of General Virology 1993, 74:65-72.
164. Peterson J.W., Bo L., Mork S., Chang A., Trapp B.D. Transected neuritis, apoptotic neurons and reduced inflammation in cortical MS lesions. Annals of Neurology 2001, 50:389-400.
165. Pewe L., Haring J., Perlman S. CD4 T cell mediated-demyelination is increased in the absence of gamma interferon in mice infected with murine hepatitis virus. Journal of Virology 2002, 76:7329-7333.
166. Pirko I., Johnson A.J., Chen Y., Lindquist D.M., Lohrey A.K., Ying J., Dunn R.S. Brain atrophy correlates with functional outcome in a murine model of multiple sclerosis. Neuroimage 2011, 54:802-806.
167. Pirko I., Johnson A.J., Lohrey A.K., Chen Y., Ying J. Deep gray matter T2 hypointensity correlates with disability in a murine model of MS. Journal of the Neurological Sciences 2009, 282:34-38.
168. Pitt D., Werner P., Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nature Medicine 2000, 6:67-70.
169. Prayoonwiwat N., Rodriguez M. The potential for oligodendrocyte proliferation during demyelinating disease. Journal of Neuropathology and Experimental Neurology 1993, 52:55-63.
170. Raine C.S., Scheinberg L., Waltz J.M. Multiple sclerosis. Oligodendrocytes survival in an active established lesion. Laboratory Investigation 1981, 45:534-546.
171. Rauch H.C., King K.M., Lewandowski L.J. Detection of cellular hypersensitivity among multiple sclerosis (MS) patients to 6/94 virus; a parainfluenza type-1 isolate from MS brain tissue. International Archives of Allergy and Applied Immunology 1975, 48:475-484.
172. Richards M.H., Getts M.T., Podojil J.R., Jin Y., Kim B.S., Miller S. Virus expanded regulatory T cells control severity in the Theiler's virus mouse model of MS. Journal of Autoimmunity 2011, 36:142-154.
173. Rivera-Quinones C., McGavern D., Schmelzer J.D., Hunte S.F., Low P.A., Rodriguez M. Absence of neurological deficits following extensive demyelination in a class I deficient murine model of multiple sclerosis. Nature Medicine 1998, 4:187-193.
174. Rivers T., Sprunt D.H., Berry G.P. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. Journal of Experimental Medicine 1933, 58:39-53.
175. Rodriguez M. Virus-induced demyelination in mice: "dyingback" of oligodendrocytes. Mayo Clinic Proceedings 1985, 60:433-438.
176. Rodriguez M., Leibowitz J., David C.S. Susceptibility to Theiler's virus-induced demyelination. Mapping of the gene within the H-2D region. Journal of Experimental Medicine 1986, 163:620-631.
177. Rodriguez M., Leibowitz J., Lampert P.W. Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. Annals of Neurology 1983, 13:426-433.
178. Rodriguez M., Lennon V.A. Immunoglobulins promote remyelination in the central nervous system. Annals of Neurology 1990, 27:12-17.
179. Rodriguez M., Lennon V.A., Benveniste E.N., Merrill J.E. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. Journal of Neuropathology and Experimental Neurology 1987, 46:84-95.
180. Rodriguez M., Lindsley M.D. Immunosuppression promotes CNS remyelination in chronic virus-induced demyelinating disease. Neurology 1992, 42:348-357.
181. Rodriguez M., Oleszak E., Leibowitz J. Theiler's virus encephalomyelitis: a model of demyelination and persistence of virus. Critical Reviews in Immunology 1987, 7:325-365.
182. Rodriguez M., Pavelko K., Njenga M., Logan W., Westtein P. The balance between persistence virus infection and immune cells determines the demyelination. Journal of Immunology 1996, 157:5699-5709.
183. Rodriguez M., Quddus J. Effect of cyclosporine A, silica quartz dust, and protease inhibitors on virus-induced demyelination. Journal of Neuroimmunology 1986, 13:159-174.
184. Rodriguez M., Sriram S. Successful therapy of Theiler's virus induced demyelination (DA strain) with monoclonal andt-Lyt-2 antibody. Journal of Immunology 1988, 140:2950-2955.
185. Rodriguez M., Warrington A.E., Pease L.R. Invited article: human natural autoantibodies in the treatment of neurologic disease. Neurology 2009, 72:1269-1276.
186. Rodriguez M., Zoecklein L.J., Howe C.L., Pavelko K.D., Gamez J.D., Nakane S., Papke L.M. Gamma interferon is critical for viral neuronal clearance and protection in a susceptible mouse strain following early intracranial Theiler's murine encephalomyelitis virus infection. Journal of Virology 2003, 77:12252-12265.
187. Roos R.P., Wollmann R. DA strain of Theiler's murine encephalomyelitis mice induces demyelination in nude mice. Annals of Neurology 1984, 15:494-499.
188. Rose J.W., Hill K.E., Wada Y. Nitric oxide synthase inhibitor aminoguanidine reduces inflammation and demyelination induced by Theiler's virus infection. Journal of Neuroimmunology 1998, 81:82-89.
189. Rosenthal A., Fujinami R.S., Lampert P.W. Mechanisms of Theiler's virus-induced demyelination in nude mice. Laboratory Investigation 1986, 54:512-522.
190. Rowell J.F., Griffin D.E. Contribution of T cells to mortality in neurovirulent Sindbis virus encephalomyelitis. Journal of Neuroimmunology 2002, 127:106-114.
191. Sargsyan S.A., Shearer A.J., Ritchie A.M., Burgoon M.P., Anderson S., Hemmer B., Stadelmann C., Gattenlöhner S., Owens G.P., Gilden D., Bennett J.L. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010, 74:1127-1135.
192. Sathornsumetee S., McGavern D.B., Ure D.R., Rodriguez M. Quantitative ultrastructural analysis of a single spinal cord demyelinated lesion predicts total lesion load axonal loss and neurological dysfunction in a murine model of multiple sclerosis. American Journal of Pathology 2000, 157:1365-1376.
193. Sato F., Tanaka H., Hasanovic F., Tsunoda I. Theiler's virus infection: pathophysiology of demyelination and neurodegeneration. Pathophysiology 2011, 18:31-41.
194. Scarisbrick I.A., Yoon H., Panos M., Larson N., Blaber S.I., Bleber M., Rodriguez M. Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis. Brain Pathology 2012, 22:709-722. 10.1111/j.1750-3639.2012.00577.x.
195. Schlitt B.P., Felrice P.M., Jelachich M.L., Lipton H.L. Apoptotic cells, including macrophages, are prominent in Theiler's virus-induced inflammatory demyelinating lesions. Journal of Virology 2003, 77:4383-4388.
196. Smith T., Groom A., Zhu B., Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nature Medicine 2000, 6:62-66.
197. Smith-Norowitz T.A., Sobel R.A., Mokhtarian F. B cells and antibodies in the pathogenesis of myelin injury in Semliki Forest virus encephalomyelitis. Cellular Immunology 2000, 25:27-35.
198. Soldan S.S., Berti R., Salem P., Secchiero P., Flamand L., Calabresi P.A., Brenann M.B., Maloni H.W., Mc Farland H.F., Lin H.C., Patnaik M., Jacobson S. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Medicine 1997, 3:1394-1397.
199. 2+ influx pathway in astrocytes and oligodendrocytes: relationship to the mechanisms of myelin repair. Molecular and Cellular Neuroscience 2003, 22:14-24.
200. Srinivasan R., Sailasuta N., Hurd R., Nelson S., Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3T. Brain 2005, 128:1016-1025.
201. Sriram A., Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Annals of Neurology 2005, 58:939-945.
202. Steiner C.M., Rozhon E.J., Lipton H.L. Relationship between host age and persistence of Theiler's virus in the central nervous system of mice. Infection and Immunity 1984, 43:432-434.
203. Steinman L., Zamvil S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends in Immunology 2005, 26:565-571.
204. Stewart K.A., Wilcox K.S., Fujinami R.S., White H.S. Development of postinfection epilepsy after Theiler's virus infection in C57BL/6 mice. Journal of Neuropathology and Experimental Neurology 2010, 69:1210-1219.
205. Stüve O., Racke M., Hemmer B. Viral pathogens in multiple sclerosis: an intriguing (hi)story. Archives of Neurology 2004, 61:1500-1502.
206. + T cells prevents lesions of demyelination in Semliki virus infection. Journal of Virology 1993, 67:7629-7633.
207. + T cells are encephalitogenic and produce severe disease in C57BL76 mice. Journal of Immunology 2001, 166:7579-7587.
208. Tait A.R., Straus S.K. Phosphorylation of U24 from Human Herpes Virus type 6 (HHV-6) and its potential role in mimicking myelin basic protein (MBP) in multiple sclerosis. FEBS Letters 2008, 582:2685-2688.
209. Theiler M. Spontaneous encephalomyelitis of mice - a new virus disease. Science 1937, 80:122.
210. Tobler L.H., Johnson K.P., Case Buerhing G. Measles or mumps virus-infected cells forming rosettes with lymphocytes from patients with multiple sclerosis. Archives of Neurology 1982, 39:565-569.
211. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annual Review of Neuroscience 2008, 31:247-269.
212. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. New England Journal of Medicine 1998, 338:278-285.
213. Trebst C., Stangel M. Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis. Current Pharmaceutical Design 2006, 12:241-249.
214. Tsunoda I. Axonal degeneration as a self-destructive defense mechanisms against neurotropic virus infection. Future Virology 2008, 3:579-593.
215. Tsunoda I., Fujinami R.S. Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination. Springer Seminars in Immunopathology 2002, 24:105-125.
216. Tsunoda I., Fujinami R.S. Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis. Journal of NeuroImmune Pharmacology 2010, 5:355-369.
217. + cytotoxic T cells during Theiler's murine encephalomyelitis virus infection: implications for autoimmunity. Journal of Virology 2002, 76:12834-12844.
218. + T cell clones following virus infection. Journal of Virology 2005, 79:14640-14646.
219. Tsunoda I., Kuang L.Q., Libbey J.E., Fujinami R.S. Axonal injury heralds virus-induced demyelination. American Journal of Pathology 2003, 162:1259-1269.
220. Tsunoda I., Kurtz C.I.B., Fujinami R.S. Apoptosis in acute and chronic central nervous system disease induced by Theiler's murine encephalomyelitis virus. Virology 1997, 228:388-393.
221. Tsunoda I., Libbey J.E., Kobayashi-Warren M., Fujinami R.S. Interferon-gamma production and astrocyte recognition by autoreactive T cells induced by Theiler's virus infection: role of viral strains and capsid proteins. Journal of Neuroimmunology 2006, 172:85-93.
222. Tsunoda I., Tanaka T., Saijoh Y., Fujinami R.S. Targeting inflammatory demyelinating lesions to sites of Wallerian degeneration. American Journal of Pathology 2007, 171:1563-1575.
223. Tsunoda I., Tanaka T., Terry E.J., Fujinami R.S. Contrasting roles for axonal degeneration in an autoimmune versus viral model of multiple sclerosis. When can axonal injury be beneficial?. American Journal of Pathology 2007, 170:214-226.
224. Tzartos J.S., Khan G., Vossenkamper A., Cruz-Sadaba M., Lonardi S., Sefia E., Meager A., Elia A., Middeldorp J.M., Clemens M., Farrell P.J., Giovannoni G., Meier U.C. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012, 78:15-23.
225. Ulrich R., Seeliger F., Kreutzer M., Germann P.G., Baumgärtner W. Limited remyelination in Theiler's virus encephalomyelitis due to insufficient oligodendroglial cells differentiation of nerve/glial antigen 2 (NG-2) positive putative oligodendroglial progenitor cells. Neuropathology and Applied Neurobiology 2008, 34:603-620.
226. Ure D.R., Rodriguez M. Preservation of neurological function during inflammatory demyelination correlates with axons sparing in a mouse model of multiple sclerosis. Neuroscience 2002, 111:399-411.
227. Van Oasten B.W., Lai M., Hodgkinson S., Barkhof F., Miller D.H., Moseley I.F., Thompson A.J., Rudge P., McDougall A., McLeod J.G., Adèr H.J., Polman C.H. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double blind, placebo controlled, MR monitored phase II trial. Neurology 1997, 49:351-357.
228. Virtanen J.O., Pietiläinen-Nicklén J., Uotila L., Färkkilä M., Vaheri A., Koskiniemi M. Intrathecal human herpes virus 6 antibodies in multiple sclerosis and other demyelinating diseases presenting as oligoclonal bands in cerebrospinal fluid. Journal of Neuroimmunology 2011, 237:93-97.
229. Warrington A.E., Asakura K., Bieber A.J., Ciric B., Van Keulen V., Kaveri S.V., Kyle R.A., Pease L.R., Rodriguez M. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:6820-6825.
230. Warrington A.E., Bieber A.J., Ciric B., Pease L.R., Van Keulen V., Rodriguez M. A recombinant human IgM promotes myelin repair after a single, very low dose. Journal of Neuroscience Research 2007, 85:967-976.
231. Warrington A.E., Bieber A.J., Van Keulen V., Ciric B., Pease L.R., Rodriguez M. Neuron-binding human monoclonal antibodies support central nervous system neurite extension. Journal of Neuropathology and Experimental Neurology 2004, 63:461-473.
232. Warrington A.E., Rodriguez M. Method of identifying natural antibodies for remyelination. Journal of Clinical Immunology 2010, 30(Suppl. 1):S50L 55.
233. Weber M.S., Steinman L., Zamvil S.S. Statins-treatment option for central nervous system autoimmune disease?. Neurotherapeutics 2007, 4:693-700.
234. Weiner H.L., Mackin G.A., Orav E.J., Hafler D.A., Dawson D.M., LaPierre Y., Herndon R., Lehrich J.R., Hauser S.L., Turel A. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993, 43:910-918.
235. Welsh C.J.R., Tonks P., Nash A.A., Blakemore W.F. The effects of L3T4 T cell depletion on the pathogenesis of Theiler's murine encephalomyelitis virus infection in CBA mice. Journal of General Virology 1987, 68:1659-1667.
236. Wright B.R., Warrington A.E., Rodriguez M. Cellular mechanisms of central nervous system repair by natural autoreactive antibodies. Archives of Neurology 2009, 66:1456-1459.
237. Wu G.F., Dandekar A.A., Pewe L., Perlman S. CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. Journal of Immunology 2000, 165:2278-2286.
238. Wu G.F., Perlman S. Macrophage infiltration but not apoptosis, is correlated with immune mediated demyelination following murine infection with a neurotropic coronavirus. Journal of Virology 1999, 73:8771-8780.
239. Yamada M., Zurbriggen A., Fujinami R.S. Monoclonal antibody to Theiler's murine encephalomyelitis virus defines a determinant on myelin and oligodendrocytes, and augments demyelination in experimental allergic encephalomyelitis. Journal of Experimental Medicine 1990, 171:1893-1907.
240. Yamada M., Zurbriggen A., Fujinami R.S. Pathogenesis of Theiler's murine encephalomyelitis virus. Advances in Virus Research 1991, 39:291-320.
241. Zajicek J., Fox P., Sanders H., Wright D., Vickery J., Nunn A., Thompson A. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomized placebo controlled trial. Lancet 2003, 362:1517-1526.
242. Zamvil S., Steinmann L. The T lymphocyte in autoimmune encephalomyelitis. Annual Review of Immunology 1990, 8:579-621.
243. Zheng L., Calenoff M.A., Dal Canto M.C. Astrocytes, not microglia are the main cells responsible for viral persistence in Theiler's murine encephalomyelitis virus infection leading to demyelination. Journal of Neuroimmunology 2001, 118:252-267.
244. Zoecklein L.J., Pavelko K.D., Gamez J., Papke L., McGavern D.B., Ure D.R., Njenga M.K., Johnson A.J., Nakane S., Rodriguez M. Direct comparison of demyelinating disease induced by the Daniels strain and BeAn strain of Theiler's murine encephalomyelitis virus. Brain Pathology 2003, 13:291-308.